DD146548A5 - Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin - Google Patents

Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin Download PDF

Info

Publication number: DD146548A5
Authority: DD; German Democratic Republic
Prior art keywords: collagen; active ingredient; weight; binder; resorbable
Prior art date: 1978-10-09

Application number

DD79216048A

Other languages

German (de)

English (en)

Inventor

Helmut Wahlig

Elvira Dingeldein

Dietrich Braun

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-10-09

Filing date

1979-10-05

Publication date

1981-02-18

1979-10-05 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

1981-02-18 Publication of DD146548A5 publication Critical patent/DD146548A5/de

Links

102000008186 Collagen Human genes 0.000 title claims abstract description 62
108010035532 Collagen Proteins 0.000 title claims abstract description 62
229920001436 collagen Polymers 0.000 title claims abstract description 62
239000004480 active ingredient Substances 0.000 claims abstract description 34
239000001506 calcium phosphate Substances 0.000 claims abstract description 32
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract description 32
239000011230 binding agent Substances 0.000 claims abstract description 27
229910000389 calcium phosphate Inorganic materials 0.000 claims abstract description 23
235000011010 calcium phosphates Nutrition 0.000 claims abstract description 23
239000000463 material Substances 0.000 claims abstract description 14
239000000203 mixture Substances 0.000 claims description 30
238000000034 method Methods 0.000 claims description 22
239000003814 drug Substances 0.000 abstract description 15
229940079593 drug Drugs 0.000 abstract description 11
238000004519 manufacturing process Methods 0.000 abstract description 4
238000001356 surgical procedure Methods 0.000 abstract description 2
238000002360 preparation method Methods 0.000 description 35
229920001577 copolymer Polymers 0.000 description 30
229930182566 Gentamicin Natural products 0.000 description 22
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 22
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical group OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 21
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 18
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 16
239000003242 anti bacterial agent Substances 0.000 description 15
239000000843 powder Substances 0.000 description 13
235000018102 proteins Nutrition 0.000 description 13
102000004169 proteins and genes Human genes 0.000 description 13
108090000623 proteins and genes Proteins 0.000 description 13
230000003115 biocidal effect Effects 0.000 description 11
238000012545 processing Methods 0.000 description 11
229940088710 antibiotic agent Drugs 0.000 description 10
210000000988 bone and bone Anatomy 0.000 description 10
239000002245 particle Substances 0.000 description 10
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 9
229910000391 tricalcium phosphate Inorganic materials 0.000 description 9
235000019731 tricalcium phosphate Nutrition 0.000 description 9
229940078499 tricalcium phosphate Drugs 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 8
229960000448 lactic acid Drugs 0.000 description 8
239000003826 tablet Substances 0.000 description 8
206010052428 Wound Diseases 0.000 description 7
208000027418 Wounds and injury Diseases 0.000 description 7
239000013543 active substance Substances 0.000 description 7
239000008187 granular material Substances 0.000 description 7
239000004310 lactic acid Substances 0.000 description 7
235000014655 lactic acid Nutrition 0.000 description 7
JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
238000002513 implantation Methods 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
238000007493 shaping process Methods 0.000 description 5
238000005245 sintering Methods 0.000 description 5
238000007792 addition Methods 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
239000007943 implant Substances 0.000 description 4
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 4
238000000465 moulding Methods 0.000 description 4
239000004033 plastic Substances 0.000 description 4
229920003023 plastic Polymers 0.000 description 4
AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 3
JRHWHSJDIILJAT-UHFFFAOYSA-N 2-hydroxypentanoic acid Chemical compound CCCC(O)C(O)=O JRHWHSJDIILJAT-UHFFFAOYSA-N 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
206010031252 Osteomyelitis Diseases 0.000 description 3
230000002421 anti-septic effect Effects 0.000 description 3
229940064004 antiseptic throat preparations Drugs 0.000 description 3
230000008468 bone growth Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000002349 favourable effect Effects 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
238000001746 injection moulding Methods 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
239000000178 monomer Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
-1 α-hydroxy-α-hydroxybutyric acid methylvaleric acid Chemical compound 0.000 description 3
GHPVDCPCKSNJDR-UHFFFAOYSA-N 2-hydroxydecanoic acid Chemical compound CCCCCCCCC(O)C(O)=O GHPVDCPCKSNJDR-UHFFFAOYSA-N 0.000 description 2
JYZJYKOZGGEXSX-UHFFFAOYSA-N 2-hydroxymyristic acid Chemical compound CCCCCCCCCCCCC(O)C(O)=O JYZJYKOZGGEXSX-UHFFFAOYSA-N 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
102000016942 Elastin Human genes 0.000 description 2
108010014258 Elastin Proteins 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
JVTAAEKCZFNVCJ-REOHCLBHSA-N L-Lactic acid Natural products C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
208000002565 Open Fractures Diseases 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
229930189077 Rifamycin Natural products 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
229940121363 anti-inflammatory agent Drugs 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
239000011324 bead Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
HSJPMRKMPBAUAU-UHFFFAOYSA-N cerium(3+);trinitrate Chemical compound [Ce+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O HSJPMRKMPBAUAU-UHFFFAOYSA-N 0.000 description 2
229960002227 clindamycin Drugs 0.000 description 2
KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
238000005520 cutting process Methods 0.000 description 2
229960003807 dibekacin Drugs 0.000 description 2
JJCQSGDBDPYCEO-XVZSLQNASA-N dibekacin Chemical compound O1[C@H](CN)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N JJCQSGDBDPYCEO-XVZSLQNASA-N 0.000 description 2
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
229920002549 elastin Polymers 0.000 description 2
238000011049 filling Methods 0.000 description 2
238000000227 grinding Methods 0.000 description 2
230000035876 healing Effects 0.000 description 2
229920001519 homopolymer Polymers 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
229960002591 hydroxyproline Drugs 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
229920001308 poly(aminoacid) Polymers 0.000 description 2
239000000047 product Substances 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
210000004872 soft tissue Anatomy 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
238000011282 treatment Methods 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
XEQLFNPSYWZPOW-NUOYRARPSA-N (2r)-4-amino-n-[(1r,2s,3r,4r,5s)-5-amino-4-[(2r,3r,4r,5s,6r)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-2-hydroxycyclohexyl]-2-hydroxybutanamide Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O[C@@H]1[C@@H]([C@H](O)[C@@H](CO)O1)O)O)NC(=O)[C@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1N XEQLFNPSYWZPOW-NUOYRARPSA-N 0.000 description 1
SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
TYBHZVUFOINFDV-UHFFFAOYSA-N 2-bromo-6-[(3-bromo-5-chloro-2-hydroxyphenyl)methyl]-4-chlorophenol Chemical compound OC1=C(Br)C=C(Cl)C=C1CC1=CC(Cl)=CC(Br)=C1O TYBHZVUFOINFDV-UHFFFAOYSA-N 0.000 description 1
RGMMREBHCYXQMA-UHFFFAOYSA-N 2-hydroxyheptanoic acid Chemical compound CCCCCC(O)C(O)=O RGMMREBHCYXQMA-UHFFFAOYSA-N 0.000 description 1
BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 description 1
KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-hydroxyoctadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 1
JKRDADVRIYVCCY-UHFFFAOYSA-N 2-hydroxyoctanoic acid Chemical compound CCCCCCC(O)C(O)=O JKRDADVRIYVCCY-UHFFFAOYSA-N 0.000 description 1
NRSJYUSYBNFGAK-UHFFFAOYSA-N 3-bromo-4-propan-2-yloxybenzoic acid Chemical compound CC(C)OC1=CC=C(C(O)=O)C=C1Br NRSJYUSYBNFGAK-UHFFFAOYSA-N 0.000 description 1
PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical class NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
108010001478 Bacitracin Proteins 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
229930182843 D-Lactic acid Natural products 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
206010063560 Excessive granulation tissue Diseases 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
206010017076 Fracture Diseases 0.000 description 1
IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
108010026389 Gramicidin Proteins 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
NGEWQZIDQIYUNV-UHFFFAOYSA-N L-valinic acid Natural products CC(C)C(O)C(O)=O NGEWQZIDQIYUNV-UHFFFAOYSA-N 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
229930183998 Lividomycin Natural products 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
TYMRLRRVMHJFTF-UHFFFAOYSA-N Mafenide Chemical compound NCC1=CC=C(S(N)(=O)=O)C=C1 TYMRLRRVMHJFTF-UHFFFAOYSA-N 0.000 description 1
229930184158 Maridomycin Natural products 0.000 description 1
DMUAPQTXSSNEDD-QALJCMCCSA-N Midecamycin Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C DMUAPQTXSSNEDD-QALJCMCCSA-N 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
YXLXNENXOJSQEI-UHFFFAOYSA-L Oxine-copper Chemical compound [Cu+2].C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1 YXLXNENXOJSQEI-UHFFFAOYSA-L 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
108010040201 Polymyxins Proteins 0.000 description 1
URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 description 1
ZUHRLTIPDRLJHR-UHFFFAOYSA-N Rosamicin Natural products CCC1OC(=O)CC(O)C(C)C(OC2OC(C)CC(C2O)N(C)C)C(CC=O)CC(C)C(=O)C=CC3OC3C1C ZUHRLTIPDRLJHR-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
229930192786 Sisomicin Natural products 0.000 description 1
206010062255 Soft tissue infection Diseases 0.000 description 1
239000004187 Spiramycin Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
FFXJTOKFQATYBI-RUTGJBPVSA-N [(1s,3r,7r,8s,9s,10r,12r,13r,14e,16s)-9-[(2s,3r,4r,5s,6r)-4-(dimethylamino)-3-hydroxy-5-[(2s,4r,5s,6s)-4-hydroxy-4,6-dimethyl-5-propanoyloxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-13-hydroxy-8-methoxy-3,12-dimethyl-5-oxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1 Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C[C@@H]3O[C@H]3/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C FFXJTOKFQATYBI-RUTGJBPVSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
229940024554 amdinocillin Drugs 0.000 description 1
229960004821 amikacin Drugs 0.000 description 1
LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
229960004909 aminosalicylic acid Drugs 0.000 description 1
229960003022 amoxicillin Drugs 0.000 description 1
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960003200 azlocillin sodium Drugs 0.000 description 1
229960003071 bacitracin Drugs 0.000 description 1
229930184125 bacitracin Natural products 0.000 description 1
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
ZGJHIFYEQJEUKA-UHFFFAOYSA-N buclosamide Chemical compound CCCCNC(=O)C1=CC=C(Cl)C=C1O ZGJHIFYEQJEUKA-UHFFFAOYSA-N 0.000 description 1
229950000430 buclosamide Drugs 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
229960003012 cefamandole Drugs 0.000 description 1
OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
229960005312 cefazedone Drugs 0.000 description 1
VTLCNEGVSVJLDN-MLGOLLRUSA-N cefazedone Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3C=C(Cl)C(=O)C(Cl)=C3)[C@H]2SC1 VTLCNEGVSVJLDN-MLGOLLRUSA-N 0.000 description 1
229960001139 cefazolin Drugs 0.000 description 1
MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
229960002682 cefoxitin Drugs 0.000 description 1
229960001668 cefuroxime Drugs 0.000 description 1
JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
MSUOLNSQHLHDAS-UHFFFAOYSA-N cerebronic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(O)C(O)=O MSUOLNSQHLHDAS-UHFFFAOYSA-N 0.000 description 1
MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
BWWVAEOLVKTZFQ-ISVUSNJMSA-N chembl530 Chemical compound N(/[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)=C\N1CCCCCC1 BWWVAEOLVKTZFQ-ISVUSNJMSA-N 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
229960003260 chlorhexidine Drugs 0.000 description 1
CTQMJYWDVABFRZ-UHFFFAOYSA-N cloxiquine Chemical compound C1=CN=C2C(O)=CC=C(Cl)C2=C1 CTQMJYWDVABFRZ-UHFFFAOYSA-N 0.000 description 1
229960004531 colistimethate sodium Drugs 0.000 description 1
IQWHCHZFYPIVRV-VLLYEMIKSA-I colistin A sodium methanesulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].CC[C@@H](C)CCCCC(=O)N[C@@H](CCNCS([O-])(=O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCNCS([O-])(=O)=O)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCNCS([O-])(=O)=O)NC(=O)[C@H](CCNCS([O-])(=O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS([O-])(=O)=O)NC1=O IQWHCHZFYPIVRV-VLLYEMIKSA-I 0.000 description 1
108700028201 colistinmethanesulfonic acid Proteins 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229960003077 cycloserine Drugs 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
229960004060 dicloxacillin sodium Drugs 0.000 description 1
SIGZQNJITOWQEF-VICXVTCVSA-M dicloxacillin sodium monohydrate Chemical compound O.[Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl SIGZQNJITOWQEF-VICXVTCVSA-M 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
229960003722 doxycycline Drugs 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
239000000835 fiber Substances 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
229960000308 fosfomycin Drugs 0.000 description 1
YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
229960004675 fusidic acid Drugs 0.000 description 1
IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
244000000058 gram-negative pathogen Species 0.000 description 1
244000000059 gram-positive pathogen Species 0.000 description 1
229960004905 gramicidin Drugs 0.000 description 1
ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
210000001126 granulation tissue Anatomy 0.000 description 1
ZFSXZJXLKAJIGS-UHFFFAOYSA-N halocarban Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(NC(=O)NC=2C=CC(Cl)=CC=2)=C1 ZFSXZJXLKAJIGS-UHFFFAOYSA-N 0.000 description 1
229950006625 halocarban Drugs 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
229960004867 hexetidine Drugs 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
229960004144 josamycin Drugs 0.000 description 1
XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
229960005287 lincomycin Drugs 0.000 description 1
OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
229950003076 lividomycin Drugs 0.000 description 1
DBLVDAUGBTYDFR-SWMBIRFSSA-N lividomycin A Chemical compound O([C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O[C@@H]1O[C@H](CO)[C@H]([C@H]1O)O[C@H]1O[C@H]([C@H]([C@H](O)[C@H]1N)O[C@@H]1[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)CN)[C@H]1O[C@H](CO)[C@@H](O)C[C@H]1N DBLVDAUGBTYDFR-SWMBIRFSSA-N 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
229940041033 macrolides Drugs 0.000 description 1
229960003640 mafenide Drugs 0.000 description 1
229950002784 maridomycin Drugs 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960002757 midecamycin Drugs 0.000 description 1
229960004023 minocycline Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
229960000808 netilmicin Drugs 0.000 description 1
ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
229960001907 nitrofurazone Drugs 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229960002950 novobiocin Drugs 0.000 description 1
YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 1
229960001194 noxytiolin Drugs 0.000 description 1
JLMHZVYLAQPMOZ-UHFFFAOYSA-N noxytiolin Chemical compound CNC(=S)NCO JLMHZVYLAQPMOZ-UHFFFAOYSA-N 0.000 description 1
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
244000052769 pathogen Species 0.000 description 1
239000008188 pellet Substances 0.000 description 1
150000002960 penicillins Chemical class 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
229960002895 phenylbutazone Drugs 0.000 description 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
229960002292 piperacillin Drugs 0.000 description 1
WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
108010054442 polyalanine Proteins 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
229940041153 polymyxins Drugs 0.000 description 1
239000003910 polypeptide antibiotic agent Substances 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
238000003825 pressing Methods 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
229960003485 ribostamycin Drugs 0.000 description 1
229930190553 ribostamycin Natural products 0.000 description 1
NSKGQURZWSPSBC-NLZFXWNVSA-N ribostamycin Chemical compound N[C@H]1[C@H](O)[C@@H](O)[C@H](CN)O[C@@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](CO)O2)O)[C@H](O)[C@@H](N)C[C@H]1N NSKGQURZWSPSBC-NLZFXWNVSA-N 0.000 description 1
NSKGQURZWSPSBC-UHFFFAOYSA-N ribostamycin A Natural products NC1C(O)C(O)C(CN)OC1OC1C(OC2C(C(O)C(CO)O2)O)C(O)C(N)CC1N NSKGQURZWSPSBC-UHFFFAOYSA-N 0.000 description 1
229960001225 rifampicin Drugs 0.000 description 1
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
229960003292 rifamycin Drugs 0.000 description 1
HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 1
229940081192 rifamycins Drugs 0.000 description 1
IUPCWCLVECYZRV-JZMZINANSA-N rosaramicin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H]([C@@H]2O[C@@]2(C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O IUPCWCLVECYZRV-JZMZINANSA-N 0.000 description 1
150000003873 salicylate salts Chemical class 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229960003600 silver sulfadiazine Drugs 0.000 description 1
229960005456 sisomicin Drugs 0.000 description 1
URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
229960002920 sorbitol Drugs 0.000 description 1
229960001294 spiramycin Drugs 0.000 description 1
235000019372 spiramycin Nutrition 0.000 description 1
229930191512 spiramycin Natural products 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
229940041022 streptomycins Drugs 0.000 description 1
229960004306 sulfadiazine Drugs 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
229960004267 taurolidine Drugs 0.000 description 1
AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
OTVAEFIXJLOWRX-NXEZZACHSA-N thiamphenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 description 1
229960003053 thiamphenicol Drugs 0.000 description 1
229960000707 tobramycin Drugs 0.000 description 1
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
KVSKGMLNBAPGKH-UHFFFAOYSA-N tribromosalicylanilide Chemical compound OC1=C(Br)C=C(Br)C=C1C(=O)NC1=CC=C(Br)C=C1 KVSKGMLNBAPGKH-UHFFFAOYSA-N 0.000 description 1
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
229960001082 trimethoprim Drugs 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
239000004474 valine Substances 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Dermatology (AREA)
Oral & Maxillofacial Surgery (AREA)
Transplantation (AREA)
Engineering & Computer Science (AREA)
Materials Engineering (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Composite Materials (AREA)
Hematology (AREA)
Biophysics (AREA)
Materials For Medical Uses (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

DD79216048A 1978-10-09 1979-10-05 Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin DD146548A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19782843963 DE2843963A1 (de)	1978-10-09	1978-10-09	Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin

Publications (1)

Publication Number	Publication Date
DD146548A5 true DD146548A5 (de)	1981-02-18

Family

ID=6051759

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD79216048A DD146548A5 (de)	1978-10-09	1979-10-05	Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin

Country Status (19)

Country	Link
US (2)	US4291013A (fr)
JP (1)	JPS5553214A (fr)
AT (1)	AT371724B (fr)
AU (1)	AU535839B2 (fr)
BE (1)	BE879252A (fr)
CA (1)	CA1142433A (fr)
CH (1)	CH642845A5 (fr)
CS (1)	CS221526B2 (fr)
DD (1)	DD146548A5 (fr)
DE (1)	DE2843963A1 (fr)
ES (1)	ES484821A0 (fr)
FR (1)	FR2438479A1 (fr)
GB (1)	GB2032777B (fr)
HU (1)	HU180019B (fr)
IL (1)	IL58397A (fr)
IT (1)	IT1164832B (fr)
NL (1)	NL7907450A (fr)
SE (1)	SE434013B (fr)
ZA (1)	ZA795356B (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3411957A1 (de) *	1983-03-31	1984-10-04	Genetic Laboratories, Inc., St. Paul, Minn.	Verfahren zur herrichtung von tierischem oder menschlichem gewebe zur verwendung als verbandsmaterial
DE3317390A1 (de) *	1983-05-13	1984-11-15	Hoechst Ag, 6230 Frankfurt	Pharmazeutisches mittel zur behandlung von knocheninfektionen
DE3523023A1 (de) *	1985-06-27	1987-01-08	Ruhland Nachf Gmbh Dr	Silberhaltige kollagenschwaemme oder kollagenfascien und deren verwendung zur herstellung eines abdeckmaterials fuer hautlaesionen
DE3832162A1 (de) *	1988-09-22	1990-04-12	Lohmann Therapie Syst Lts	Verfahren zur herstellung von kollagenschaeumen in form endloser baender und verwendung in medizin, kosmetik und hygiene
DE3912693A1 (de) *	1989-04-18	1990-10-25	Bioprotan Handels Gmbh	Verbundmaterial fuer kosmetische zwecke
DE4143239A1 (de) *	1991-12-31	1993-07-01	Joerg Dipl Chem Schierholz	Pharmazeutische wirkstoffe enthaltende implantierbare vorrichtung aus einem polymeren material sowie verfahren zu deren herstellung
DE102019000322A1 (de)	2019-01-14	2020-07-16	Beuth Hochschule Für Technik Berlin	Polymerzusammensetzung mit antiseptischen Eigenschaften und Verfahren zur Herstellung
DE102019000321A1 (de)	2019-01-14	2020-07-16	Beuth Hochschule Für Technik Berlin	Orale Polymerzusammensetzung mit verzögerter Freisetzung
DE102020007979A1 (de)	2020-12-29	2022-06-30	Charité Universitätsmedizin Institut für Mikrobiologie und Infektionsimmunologie	Zusammensetzung zur Behandlung von lnfektionen mit Coronaviren

Families Citing this family (250)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2843963A1 (de) *	1978-10-09	1980-04-24	Merck Patent Gmbh	Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin
CA1190855A (fr) *	1980-09-03	1985-07-23	Rolf W. Pfirrmann	Traitement de l'osteite
DE3042860A1 (de) *	1980-11-13	1982-06-09	Heyl & Co Chemisch-Pharmazeutische Fabrik, 1000 Berlin	Kollagenpraeparate, verfahren zu ihrer herstellung und ihre verwendung in der human- und veterinaermedizin
GB2091554B (en) *	1981-01-13	1984-09-12	Mitsui Toatsu Chemicals	Rod like moulded drug
JPS57128621A (en) *	1981-01-30	1982-08-10	Japan Atom Energy Res Inst	Preparation of prolonged release type composite
DK154260C (da) *	1981-02-20	1989-05-22	Mundipharma Gmbh	Fremgangsmaade til fremstilling af et knogleimplantat af braendt tricalciumphosphat, specielt til udfyldning af hulrum eller til sammensaetning af knogledele efter fraktur.
US4472840A (en) *	1981-09-21	1984-09-25	Jefferies Steven R	Method of inducing osseous formation by implanting bone graft material
FR2520229A1 (fr) *	1982-01-26	1983-07-29	Japan Atomic Energy Res Inst	Procede de production d'un compose a degagement lent
EP0086627B1 (fr) *	1982-02-12	1985-08-28	Unitika Ltd.	Produit anti-cancéreux
DE3206726A1 (de) *	1982-02-25	1983-09-01	Merck Patent Gmbh, 6100 Darmstadt	Pharmakadepot
US4570629A (en) *	1982-03-17	1986-02-18	University Of Illinois Foundation	Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same
JPS58170711A (ja) *	1982-03-31	1983-10-07	Japan Atom Energy Res Inst	徐放性複合体の製造方法
FR2524312B1 (fr) *	1982-04-01	1985-10-04	Tech Cuir Centre	Nouvelles formes de micro-encapsulation de substances medicamenteuses par des couches homogenes de collagene natif
JPS58225008A (ja) *	1982-06-25	1983-12-27	Japan Atom Energy Res Inst	徐放性複合体の製造方法
DE3374659D1 (en) *	1983-02-03	1988-01-07	Ethicon Inc	Paste for hemostasis and for temporary relief of defects in the traumatism of bones
US4801299A (en) *	1983-06-10	1989-01-31	University Patents, Inc.	Body implants of extracellular matrix and means and methods of making and using such implants
JPH0738880B2 (ja) *	1983-06-24	1995-05-01	東レ株式会社	エンドトキシン血症治療剤
US4525495A (en) *	1983-07-22	1985-06-25	The Dow Chemical Company	Mineral filled composites
DE3334595A1 (de) *	1983-09-24	1985-04-18	B. Braun Melsungen Ag, 3508 Melsungen	Wirkstoffdepot
US4774091A (en) *	1983-10-14	1988-09-27	Sumitomo Pharmaceuticals Company, Ltd.	Long-term sustained-release preparation
JPH0657658B2 (ja) *	1985-04-11	1994-08-03	住友製薬株式会社	徐放性製剤
US4855134A (en) *	1983-10-14	1989-08-08	Sumitomo Pharmaceuticals Company, Limited	Sustained-release preparation
US5385738A (en) *	1983-10-14	1995-01-31	Sumitomo Pharmaceuticals Company, Ltd.	Sustained-release injection
GB8328074D0 (en) *	1983-10-20	1983-11-23	Geistlich Soehne Ag	Chemical compositions
DE3546875C2 (de) *	1984-01-30	1996-05-09	Meadox Medicals Inc	Aufschlämmung von Kollagenfibrillen zum blutdichten Beschichten eines flüssigkeitsdurchlässigen synthetischen Gefäßersatz-Substrats
IL74180A (en) *	1984-01-30	1992-06-21	Meadox Medicals Inc	Drug delivery collagen-impregnated synthetic vascular graft
IL74179A (en) *	1984-01-30	1992-05-25	Meadox Medicals Inc	Collagen synthetic vascular graft
FR2559780B1 (fr) *	1984-02-21	1990-05-04	Tech Cuir Centre	Systemes biocompatibles implantables a base de collagene permettant la conservation et/ou la culture cellulaires et/ou la liberation controlee de principes actifs
DE3414924A1 (de) *	1984-04-19	1985-10-31	Klaus Dr.med. Dr.med.habil. 8000 München Draenert	Beschichtetes verankerungsteil fuer implantate
US4596574A (en) *	1984-05-14	1986-06-24	The Regents Of The University Of California	Biodegradable porous ceramic delivery system for bone morphogenetic protein
US4619913A (en) *	1984-05-29	1986-10-28	Matrix Pharmaceuticals, Inc.	Treatments employing drug-containing matrices for introduction into cellular lesion areas
USRE35748E (en) *	1984-05-29	1998-03-17	Matrix Pharmaceutical, Inc.	Treatments employing drug containing matrices for introduction into cellular lesion areas
NL8402534A (nl) *	1984-08-17	1986-03-17	Gerrit Johannes Brinks	Materiaal, geschikt voor toepassing als implantatiemateriaal bij mens en dier ter vervanging van afwezig botweefsel, alsmede werkwijze ter bereiding van het materiaal.
FR2570606A1 (fr) *	1984-09-26	1986-03-28	Landanger Laboratoire	Obturateur notamment de puits femoral ou de fond de cotyle
US5522894A (en) *	1984-12-14	1996-06-04	Draenert; Klaus	Bone replacement material made of absorbable beads
US4595713A (en) *	1985-01-22	1986-06-17	Hexcel Corporation	Medical putty for tissue augmentation
US4842604A (en) *	1985-02-19	1989-06-27	The Dow Chemical Company	Composites of unsintered calcium phosphates and synthetic biodegradable polymers useful as hard tissue prosthetics
US4698375A (en) *	1985-02-19	1987-10-06	The Dow Chemical Company	Composites of unsintered calcium phosphates and synthetic biodegradable polymers useful as hard tissue prosthetics
US4636526A (en) *	1985-02-19	1987-01-13	The Dow Chemical Company	Composites of unsintered calcium phosphates and synthetic biodegradable polymers useful as hard tissue prosthetics
US4661536A (en) *	1985-02-19	1987-04-28	The Dow Chemical Company	Process for the preparation of hard tissue prosthetics
DE3513938A1 (de) *	1985-04-18	1986-10-23	Merck Patent Gmbh, 6100 Darmstadt	Cytostatikahaltiges pharmakadepot
IL76079A (en) *	1985-08-13	1991-03-10	Univ Ramot	Collagen implants
CS253042B1 (en) *	1985-09-25	1987-10-15	Maxmilian Mozisek	Haemostatical material
IT1181737B (it) *	1985-11-26	1987-09-30	Pierfrancesco Morganti	Supproto di collagene biologicamente attivo per uso cosmetico e farmaceutico e metodo per prepararlo
DE3542972A1 (de) *	1985-12-05	1987-06-11	Merck Patent Gmbh	Pharmakadepot
CH667874A5 (fr) *	1985-12-19	1988-11-15	Battelle Memorial Institute	Polypeptide synthetique biodegradable et son utilisation pour la preparation de medicaments.
FR2591892B1 (fr) *	1985-12-23	1988-09-16	Pf Medicament	Association collagene/principe actifantiseptique et/ou anti-inflammatoire a titre de composition, son procede de preparation et son utilisation pour la fabrication d'une composition pharmaceutique
EP0230647B1 (fr) *	1985-12-27	1993-03-31	Sumitomo Pharmaceuticals Company, Limited	Procédé pour la préparation d'une formulation à action retardée
US4774227A (en) *	1986-02-14	1988-09-27	Collagen Corporation	Collagen compositions for bone repair containing autogeneic marrow
US5904718A (en) *	1986-03-27	1999-05-18	Biocoll Laboratories, Inc.	Delayed drug delivery system
DE3613213A1 (de) *	1986-04-18	1987-10-22	Merck Patent Gmbh	Tricalciumphosphat fuer implantationsmaterialien
CA1257199A (fr) *	1986-05-20	1989-07-11	Paul Y. Wang	Preparation contenant une substance macromoleculaire ayant des proprietes biologiques liberee pendant plusieurs mois in vivo
IT1197481B (it) *	1986-09-15	1988-11-30	Zambon Spa	Preparazione farmaceutica per uso veterinario
US4865602A (en) *	1986-11-06	1989-09-12	Collagen Corporation	Gamma irradiation of collagen/mineral mixtures
FR2611496B1 (fr) *	1987-03-04	1992-07-03	Gueyne Jean	Organo-silicies cosmetiques
CA1324083C (fr) *	1987-03-09	1993-11-09	Tetsu Miyoshi	Preparations pharmaceutiques renfermant des anti-inflammatoires non steroidiens
US5085861A (en) *	1987-03-12	1992-02-04	The Beth Israel Hospital Association	Bioerodable implant composition comprising crosslinked biodegradable polyesters
US4843112A (en) *	1987-03-12	1989-06-27	The Beth Israel Hospital Association	Bioerodable implant composition
NZ224549A (en) *	1987-05-29	1990-04-26	Ici Australia Operations	Controlled release polymer microspheres containing at least one active agent
US5306311A (en) *	1987-07-20	1994-04-26	Regen Corporation	Prosthetic articular cartilage
US5681353A (en) *	1987-07-20	1997-10-28	Regen Biologics, Inc.	Meniscal augmentation device
US5116374A (en) *	1989-03-02	1992-05-26	Regen Corporation	Prosthetic meniscus
US5263984A (en) *	1987-07-20	1993-11-23	Regen Biologics, Inc.	Prosthetic ligaments
US4880429A (en) *	1987-07-20	1989-11-14	Stone Kevin R	Prosthetic meniscus
US5158574A (en) *	1987-07-20	1992-10-27	Regen Corporation	Prosthetic meniscus
US5735902A (en) *	1987-07-20	1998-04-07	Regen Biologics, Inc.	Hand implant device
CA1339083C (fr) *	1987-11-13	1997-07-29	Steven R. Jefferies	Substance pour reparation osseuse et systeme d'administration-retard de medicament
US5139527A (en) *	1987-12-17	1992-08-18	Immuno Aktiengesellschaft	Biologic absorbable implant material for filling and closing soft tissue cavities and method of its preparation
ATE90570T1 (de) *	1988-01-29	1993-07-15	Sumitomo Pharma	Verbesserte formulierungen mit kontrollierter abgabe.
US5201745A (en) *	1988-03-15	1993-04-13	Imedex	Visceral surgery patch
EP0406315B1 (fr) *	1988-03-24	1992-11-11	Bukh Meditec A/S	Composition a diffusion regulee
US5447966A (en) *	1988-07-19	1995-09-05	United States Surgical Corporation	Treating bioabsorbable surgical articles by coating with glycerine, polalkyleneoxide block copolymer and gelatin
US5573771A (en) *	1988-08-19	1996-11-12	Osteomedical Limited	Medicinal bone mineral products
US5819748A (en) *	1988-11-30	1998-10-13	Ed Geistlich Sohne Ag Fur Chemische Industrie	Implant for use in bone surgery
DE3841397A1 (de) *	1988-12-08	1990-06-21	Melzer Wolfgang	Poroeser resorbierbarer arzneistofftraeger
US4975280A (en) *	1989-01-23	1990-12-04	Ethyl Corporation	Bioerodable sustained release implants
JP2805086B2 (ja) *	1989-06-20	1998-09-30	グンゼ株式会社	生体組織用充填材
FR2649982B1 (fr) *	1989-07-20	1991-09-27	Inst Nat Sante Rech Med	Membrane biologique artificielle
US5061286A (en) *	1989-08-18	1991-10-29	Osteotech, Inc.	Osteoprosthetic implant
DE58908155D1 (de) *	1989-09-15	1994-09-08	N Proizv Ob Edinenie Kompleksn	Endoprothese des hüftgelenks.
US5081106A (en) *	1990-07-16	1992-01-14	The Oregon Health Sciences University	Wound dressing protocol utilizing collagen gelatin formed with iodine
US5128136A (en) *	1990-07-16	1992-07-07	The Oregon Health Sciences University	Wound healing kit comprised of gelable collagen
WO1992013547A1 (fr) *	1991-02-07	1992-08-20	Alexander Mellon Eaton	Composition servant a liberer un medicament et procede d'utilisation de la composition
DE4119140C2 (de) *	1991-06-11	1994-05-11	Merz & Co Gmbh & Co	Poröser, in Körperflüssigkeiten und Sekreten löslicher, spongoider Formkörper, dessen Herstellung und Verwendung
AU2572692A (en)	1991-09-09	1993-04-05	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Methods and devices for treating hemophilia and aids
DE69226197T2 (de) *	1991-11-08	1999-02-11	Somatogen, Inc., Boulder	Hämoglobine als arzneimittelabgabesystem
US5219980A (en) *	1992-04-16	1993-06-15	Sri International	Polymers biodegradable or bioerodiable into amino acids
US5641518A (en) *	1992-11-13	1997-06-24	Purdue Research Foundation	Method of repairing bone tissue
US5939191A (en) *	1993-06-11	1999-08-17	United States Surgical Corporation	Coated gut suture
US5925065A (en) *	1993-06-11	1999-07-20	United States Surgical Corporation	Coated gut suture
US5676698A (en) *	1993-09-07	1997-10-14	Datascope Investment Corp.	Soft tissue implant
GB2281709B (en) *	1993-09-14	1998-04-08	Fujitsu Ltd	Biodegradable resin moulded article
US5942496A (en) *	1994-02-18	1999-08-24	The Regent Of The University Of Michigan	Methods and compositions for multiple gene transfer into bone cells
US5962427A (en) *	1994-02-18	1999-10-05	The Regent Of The University Of Michigan	In vivo gene transfer methods for wound healing
US6074840A (en) *	1994-02-18	2000-06-13	The Regents Of The University Of Michigan	Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
US5763416A (en) *	1994-02-18	1998-06-09	The Regent Of The University Of Michigan	Gene transfer into bone cells and tissues
US20020193338A1 (en) *	1994-02-18	2002-12-19	Goldstein Steven A.	In vivo gene transfer methods for wound healing
DE4414755C2 (de) *	1994-04-27	2000-11-16	Lohmann Therapie Syst Lts	Kollagenzubereitung zur gesteuerten Abgabe von Wirkstoffen, Verfahren und Verwendung
US5928667A (en) *	1994-06-24	1999-07-27	University Of Maryland	Drug delivery device and method for employing the same
AU700584C (en) *	1994-08-12	2002-03-28	Meadox Medicals, Inc.	Vascular graft impregnated with a heparin-containing collagen sealant
US5665114A (en) *	1994-08-12	1997-09-09	Meadox Medicals, Inc.	Tubular expanded polytetrafluoroethylene implantable prostheses
DE69534233T2 (de)	1994-09-16	2005-10-27	Ethicon Endo-Surgery, Inc., Cincinnati	Vorrichtungen zum bestimmen und markieren von gewebe
US6180606B1 (en)	1994-09-28	2001-01-30	Gensci Orthobiologics, Inc.	Compositions with enhanced osteogenic potential, methods for making the same and uses thereof
US5707962A (en) *	1994-09-28	1998-01-13	Gensci Regeneration Sciences Inc.	Compositions with enhanced osteogenic potential, method for making the same and therapeutic uses thereof
US5584858A (en) *	1994-11-14	1996-12-17	United States Surgical Corporation	Tubing fluid
US5584857A (en) *	1994-11-14	1996-12-17	United States Surgical Corporation	Suture coating and tubing fluid
US7001328B1 (en) *	1994-11-15	2006-02-21	Kenton W. Gregory	Method for using tropoelastin and for producing tropoelastin biomaterials
US5788959A (en) *	1995-04-24	1998-08-04	University Of Maryland, Baltimore County	Drug delivery device and method for employing the same
US5750146A (en) *	1995-04-28	1998-05-12	Matrix Pharmaceutical, Inc.	Translucent collagen formulations with a cytotoxic drug
US6541037B1 (en)	1995-05-19	2003-04-01	Etex Corporation	Delivery vehicle
US6132463A (en) *	1995-05-19	2000-10-17	Etex Corporation	Cell seeding of ceramic compositions
US6283951B1 (en) *	1996-10-11	2001-09-04	Transvascular, Inc.	Systems and methods for delivering drugs to selected locations within the body
US6090063A (en) *	1995-12-01	2000-07-18	C. R. Bard, Inc.	Device, system and method for implantation of filaments and particles in the body
GB2311027B (en) *	1996-03-15	1999-10-27	Johnson & Johnson Medical	Coated bioabsorbable beads for wound treatment
US5668288A (en) *	1996-04-16	1997-09-16	Depuy Orthopaedics, Inc.	Polyester ionomers for implant fabrication
US6299905B1 (en)	1996-04-16	2001-10-09	Depuy Orthopaedics, Inc.	Bioerodable polymeric adhesives for tissue repair
US8716227B2 (en) *	1996-08-23	2014-05-06	Cook Biotech Incorporated	Graft prosthesis, materials and methods
CZ54899A3 (cs) *	1996-08-23	1999-08-11	Cook Biotech, Incorporated	Štěpová protéza, materiály s ní spojené a způsoby její výroby
US6666892B2 (en) *	1996-08-23	2003-12-23	Cook Biotech Incorporated	Multi-formed collagenous biomaterial medical device
US7871637B2 (en)	1996-08-27	2011-01-18	Baxter International Inc.	Dry hemostatic compositions and methods for their preparation
US7435425B2 (en) *	2001-07-17	2008-10-14	Baxter International, Inc.	Dry hemostatic compositions and methods for their preparation
US6066325A (en) *	1996-08-27	2000-05-23	Fusion Medical Technologies, Inc.	Fragmented polymeric compositions and methods for their use
US8603511B2 (en)	1996-08-27	2013-12-10	Baxter International, Inc.	Fragmented polymeric compositions and methods for their use
US8303981B2 (en)	1996-08-27	2012-11-06	Baxter International Inc.	Fragmented polymeric compositions and methods for their use
US7320962B2 (en)	1996-08-27	2008-01-22	Baxter International Inc.	Hemoactive compositions and methods for their manufacture and use
US6706690B2 (en)	1999-06-10	2004-03-16	Baxter Healthcare Corporation	Hemoactive compositions and methods for their manufacture and use
US5932539A (en) *	1996-10-15	1999-08-03	The Board Of Trustees Of The University Of Illinois	Biodegradable polymer matrix for tissue repair
AU734691B2 (en)	1996-10-16	2001-06-21	Life Science Enterprises, Inc.	Bioceramic compositions
US8728536B2 (en) *	1996-10-16	2014-05-20	Etex Corporation	Chemotherapeutic composition using nanocrystalline calcium phosphate paste
DE19713229A1 (de) *	1997-04-01	1998-10-08	Merck Patent Gmbh	Antibiotikumhaltige Knochenzementpaste
US6117444A (en) *	1997-04-10	2000-09-12	Brigham & Women's Hospital	Polyethylene glycol/microfibrillar collagen composite serves as a resorbable hemostatic agent
EP1007673B1 (fr)	1997-07-30	2008-12-17	Emory University	Nouvelle proteine de mineralisation osseuse, adn, vecteurs et systemes d'expressions
US7923250B2 (en)	1997-07-30	2011-04-12	Warsaw Orthopedic, Inc.	Methods of expressing LIM mineralization protein in non-osseous cells
US6391336B1 (en) *	1997-09-22	2002-05-21	Royer Biomedical, Inc.	Inorganic-polymer complexes for the controlled release of compounds including medicinals
US8668737B2 (en)	1997-10-10	2014-03-11	Senorx, Inc.	Tissue marking implant
US6517869B1 (en)	1997-12-12	2003-02-11	Expression Genetics, Inc.	Positively charged poly(alpha-(omega-aminoalkyl)lycolic acid) for the delivery of a bioactive agent via tissue and cellular uptake
JP3483753B2 (ja) *	1997-12-29	2004-01-06	タキロン株式会社	生体内分解吸収性可塑性粘着物
US6287693B1 (en)	1998-02-25	2001-09-11	John Claude Savoir	Stable shaped particles of crystalline organic compounds
US7691829B2 (en) *	1998-03-24	2010-04-06	Petito George D	Composition and method for healing tissues
US20050208114A1 (en) *	1998-03-24	2005-09-22	Petito George D	Composition and method for healing tissues
US20030007991A1 (en) *	1998-09-25	2003-01-09	Masters David B.	Devices including protein matrix materials and methods of making and using thereof
US7662409B2 (en) *	1998-09-25	2010-02-16	Gel-Del Technologies, Inc.	Protein matrix materials, devices and methods of making and using thereof
US20050147690A1 (en) *	1998-09-25	2005-07-07	Masters David B.	Biocompatible protein particles, particle devices and methods thereof
US6110484A (en) *	1998-11-24	2000-08-29	Cohesion Technologies, Inc.	Collagen-polymer matrices with differential biodegradability
EP1051116B8 (fr) *	1998-12-01	2009-06-10	Washington University	Dispositif d'embolisation
US8882850B2 (en) *	1998-12-01	2014-11-11	Cook Biotech Incorporated	Multi-formed collagenous biomaterial medical device
WO2000035510A1 (fr)	1998-12-14	2000-06-22	Osteotech, Inc.	Greffe osseuse et procede de regeneration osseuse guidee
US6371904B1 (en)	1998-12-24	2002-04-16	Vivant Medical, Inc.	Subcutaneous cavity marking device and method
US6356782B1 (en)	1998-12-24	2002-03-12	Vivant Medical, Inc.	Subcutaneous cavity marking device and method
US9669113B1 (en)	1998-12-24	2017-06-06	Devicor Medical Products, Inc.	Device and method for safe location and marking of a biopsy cavity
US8498693B2 (en)	1999-02-02	2013-07-30	Senorx, Inc.	Intracorporeal marker and marker delivery device
US7983734B2 (en)	2003-05-23	2011-07-19	Senorx, Inc.	Fibrous marker and intracorporeal delivery thereof
US6862470B2 (en)	1999-02-02	2005-03-01	Senorx, Inc.	Cavity-filling biopsy site markers
US8361082B2 (en) *	1999-02-02	2013-01-29	Senorx, Inc.	Marker delivery device with releasable plug
US20090216118A1 (en)	2007-07-26	2009-08-27	Senorx, Inc.	Polysaccharide markers
US9820824B2 (en)	1999-02-02	2017-11-21	Senorx, Inc.	Deployment of polysaccharide markers for treating a site within a patent
DE19912360A1 (de) *	1999-03-19	2000-09-21	Aesculap Ag & Co Kg	Strangförmiges Implantat aus resorbierbarem Polymermaterial, Verfahren zu seiner Herstellung und Anwendung in der Chirurgie
US6576246B1 (en) *	1999-05-24	2003-06-10	Seefar Technologies, Inc.	Degradable animal chewing article possessing enhanced safety, durability and mouth-feel
US6575991B1 (en)	1999-06-17	2003-06-10	Inrad, Inc.	Apparatus for the percutaneous marking of a lesion
US6441073B1 (en)	1999-08-17	2002-08-27	Taki Chemical Co., Ltd.	Biological materials
US20030228288A1 (en)	1999-10-15	2003-12-11	Scarborough Nelson L.	Volume maintaining osteoinductive/osteoconductive compositions
US6387098B1 (en)	1999-10-21	2002-05-14	Peter Alexander Cole	Intramedullary catheter nail apparatus and method
US20040009228A1 (en) *	1999-11-30	2004-01-15	Pertti Tormala	Bioabsorbable drug delivery system for local treatment and prevention of infections
US6579533B1 (en)	1999-11-30	2003-06-17	Bioasborbable Concepts, Ltd.	Bioabsorbable drug delivery system for local treatment and prevention of infections
JP2003525703A (ja) *	2000-03-09	2003-09-02	シンタコールアーゲー	人および獣の医薬に使用するための改良された性質を備えた新規な天然ポリマーを基材とする材料およびその製造方法
US9387094B2 (en)	2000-07-19	2016-07-12	Warsaw Orthopedic, Inc.	Osteoimplant and method of making same
US7323193B2 (en)	2001-12-14	2008-01-29	Osteotech, Inc.	Method of making demineralized bone particles
DE10114245A1 (de) *	2001-03-22	2002-10-02	Heraeus Kulzer Gmbh & Co Kg	Herstellung und Verwendung einer Antibiotikum-/Antibiotika-Zubereitung
DE10114364A1 (de) *	2001-03-22	2002-10-02	Heraeus Kulzer Gmbh & Co Kg	Verfahren zur Herstellung von antibiotischen Kompositen
DE10114244A1 (de) *	2001-03-22	2002-10-02	Heraeus Kulzer Gmbh & Co Kg	Antibiotikum-/Antibiotika-Zubereitung mit retardierender Wirkstofffreisetzung
US8465516B2 (en) *	2001-07-26	2013-06-18	Oregon Health Science University	Bodily lumen closure apparatus and method
US9861517B2 (en)	2001-07-26	2018-01-09	Cook Medical Technologies Llc	Vessel closure member, delivery apparatus, and method of inserting the member
IS6389A (is) *	2001-08-31	2003-03-03	Heraeus Kulzer Gmbh & Co. Kg	Reynsla af sýklalyfjahúðun skrokka, sem í eru örholrými, og einnig af þannig húðuðum skrokkum og notkun þeirra
IS6390A (is) *	2001-08-31	2003-03-03	Heraeus Kulzer Gmbh & Co. Kg	Reynsla af sýklalyfjahúðun skrokka sem í eru örholrými, þannig húðuðum skrokkum og einnig af notkunþeirra
US7163691B2 (en)	2001-10-12	2007-01-16	Osteotech, Inc.	Bone graft
US8623393B2 (en) *	2002-04-29	2014-01-07	Gel-Del Technologies, Inc.	Biomatrix structural containment and fixation systems and methods of use thereof
DE10227938B4 (de) *	2002-06-21	2006-07-20	Heraeus Kulzer Gmbh	Pharmazeutische Zubereitung, Verfahren zu ihrer Herstellung sowie deren Verwendung
DE10262176B4 (de) *	2002-06-21	2007-10-04	Heraeus Kulzer Gmbh	Verfahren zur Herstellung von antibiotisch beschichteten porösen Körpern sowie Verwendung
KR101476067B1 (ko)	2002-09-06	2014-12-23	인설트 테라페틱스, 인코퍼레이티드	공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
US20060036158A1 (en)	2003-11-17	2006-02-16	Inrad, Inc.	Self-contained, self-piercing, side-expelling marking apparatus
US20060076295A1 (en)	2004-03-15	2006-04-13	The Trustees Of Columbia University In The City Of New York	Systems and methods of blood-based therapies having a microfluidic membraneless exchange device
US20040225249A1 (en)	2003-03-14	2004-11-11	Leonard Edward F.	Systems and methods of blood-based therapies having a microfluidic membraneless exchange device
US8221781B2 (en) *	2003-04-11	2012-07-17	Etex Corporation	Osteoinductive bone material
US7877133B2 (en)	2003-05-23	2011-01-25	Senorx, Inc.	Marker or filler forming fluid
US8834864B2 (en) *	2003-06-05	2014-09-16	Baxter International Inc.	Methods for repairing and regenerating human dura mater
KR20060031808A (ko) *	2003-06-11	2006-04-13	오스테오테크, 인코포레이티드	뼈 임플란트 및 그의 제조 방법
US8465537B2 (en) *	2003-06-17	2013-06-18	Gel-Del Technologies, Inc.	Encapsulated or coated stent systems
GB2408206B (en) *	2003-11-18	2007-11-28	Johnson & Johnson Medical Ltd	Antioxidant and antimicrobial wound dressing materials
US7927626B2 (en) *	2003-08-07	2011-04-19	Ethicon, Inc.	Process of making flowable hemostatic compositions and devices containing such compositions
WO2005034852A2 (fr)	2003-08-26	2005-04-21	Gel-Del Technologies, Inc.	Biomateriaux et biocoacervats proteiniques, leurs procedes de fabrication et d'utilisation
US7309232B2 (en) *	2003-10-10	2007-12-18	Dentigenix Inc.	Methods for treating dental conditions using tissue scaffolds
WO2005055945A2 (fr) *	2003-12-08	2005-06-23	Gel-Del Technologies, Inc.	Dispositifs d'administration de medicaments mucoadhesifs et procedes de fabrication et d'utilisation associes
NZ550667A (en) *	2004-04-15	2010-10-29	Etex Corp	Delayed-setting calcium phosphate pastes for the treatment of orthopedic conditions
DE102004022645A1 (de) *	2004-05-07	2005-12-15	Resorba Wundversorgung Gmbh & Co. Kg	Bioresorbierbares Material auf Kollagen-Basis
US10357328B2 (en)	2005-04-20	2019-07-23	Bard Peripheral Vascular, Inc. and Bard Shannon Limited	Marking device with retractable cannula
WO2007056671A1 (fr)	2005-11-02	2007-05-18	Osteotech, Inc.	Greffe osseuse hemostatique
US8147860B2 (en)	2005-12-06	2012-04-03	Etex Corporation	Porous calcium phosphate bone material
EP2019658B1 (fr)	2006-05-22	2012-01-25	The Trustees of Columbia University in the City of New York	Procédé d'échange microfluidique sans membrane dans un filtre h, dans lequel les effluents d'un fluide d'extraction sont filtrés
MX2008014847A (es) *	2006-05-31	2009-04-30	Baxter Int	Metodo para crecimiento interno en la celula dirigido y regeneracion controlada de los tejidos en la cirugia espinal.
TWI436793B (zh)	2006-08-02	2014-05-11	巴克斯特國際公司	快速作用之乾密封膠及其使用和製造方法
US20090171198A1 (en) *	2006-08-04	2009-07-02	Jones Michael L	Powdered marker
US9579077B2 (en)	2006-12-12	2017-02-28	C.R. Bard, Inc.	Multiple imaging mode tissue marker
US8401622B2 (en)	2006-12-18	2013-03-19	C. R. Bard, Inc.	Biopsy marker with in situ-generated imaging properties
US20080176958A1 (en)	2007-01-24	2008-07-24	Insert Therapeutics, Inc.	Cyclodextrin-based polymers for therapeutics delivery
TWI461227B (zh)	2007-10-30	2014-11-21	Baxter Int	再生生物功能性膠原生物基質用來治療內臟或體壁缺陷的用途
US11890371B2 (en) *	2007-12-26	2024-02-06	Petvivo Holdings, Inc.	Biocompatible protein-based particles and methods thereof
US20090177203A1 (en)	2008-01-04	2009-07-09	Inbone Technologies, Inc.	Devices, systems and methods for re-alignment of bone
BRPI0907473A2 (pt)	2008-02-04	2019-09-24	Univ Columbia	métodos, sistemas e dispositivos de separação de fluidos
EP2259803B2 (fr)	2008-02-29	2019-03-13	Ferrosan Medical Devices A/S	Dispositif pour la promotion de l homéostasie et/ou la cicatrisation des plaies
US9327061B2 (en)	2008-09-23	2016-05-03	Senorx, Inc.	Porous bioabsorbable implant
US8722075B2 (en)	2008-10-24	2014-05-13	Warsaw Orthopedic, Inc.	Compositions and methods for promoting bone formation
US10016534B2 (en)	2008-11-17	2018-07-10	Gel-Del Technologies, Inc.	Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof
JP5453453B2 (ja)	2008-12-30	2014-03-26	シー・アール・バード・インコーポレーテッド	組織マーカの配置のためのマーカ伝送装置
US9039783B2 (en)	2009-05-18	2015-05-26	Baxter International, Inc.	Method for the improvement of mesh implant biocompatibility
ES2532428T3 (es)	2009-06-16	2015-03-26	Baxter International Inc	Esponja hemostática
CN102781237A (zh) *	2009-11-23	2012-11-14	天蓝制药公司	用于传递治疗剂的基于环糊精的聚合物
MX2012007056A (es)	2009-12-16	2012-09-28	Baxter Healthcare Sa	Esponja hemostatica.
WO2011119995A2 (fr)	2010-03-26	2011-09-29	Cerulean Pharma Inc.	Formulations et procédés d'utilisation
SA111320355B1 (ar)	2010-04-07	2015-01-08	Baxter Heathcare S A	إسفنجة لايقاف النزف
WO2011151386A1 (fr)	2010-06-01	2011-12-08	Baxter International Inc.	Procédé de fabrication de compositions hémostatiques sous forme sèche et stable
EP2575775B1 (fr)	2010-06-01	2018-04-04	Baxter International Inc.	Procédé de fabrication de compositions hémostatiques sous forme sèche et stable
JP6289096B2 (ja)	2010-06-01	2018-03-07	バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒＩｎｔｅｒｎａｔｉｏｎａｌＩｎｃｏｒｐ０Ｒａｔｅｄ	乾燥した安定な止血組成物を作製するためのプロセス
EP2741676A1 (fr)	2011-08-09	2014-06-18	Cook General Biotechnology LLC	Flacon utilisable dans des procédures d'extraction de tissu
EP4137165A1 (fr)	2011-10-11	2023-02-22	Baxter International Inc.	Compositions hémostatiques
AU2012318258B2 (en)	2011-10-11	2015-07-09	Baxter Healthcare S.A.	Hemostatic compositions
WO2013060770A1 (fr)	2011-10-27	2013-05-02	Baxter International Inc.	Compositions hémostatiques
RU2657955C2 (ru)	2012-03-06	2018-06-18	Ферросан Медикал Дивайсиз А/С	Контейнер под давлением, содержащий гемостатическую пасту
RU2636240C2 (ru)	2012-06-12	2017-11-21	Ферросан Медикал Дивайсиз А/С	Сухая гемостатическая композиция
US9364273B2 (en) *	2012-08-15	2016-06-14	DePuy Synthes Products, Inc.	Drug eluting surgical screw
US20140094432A1 (en)	2012-10-02	2014-04-03	Cerulean Pharma Inc.	Methods and systems for polymer precipitation and generation of particles
DE102012023348B4 (de) *	2012-11-29	2016-09-29	Hochschule München	Verfahren zur Untersuchung eines Wirkstoffdepots mittels eines bildgebenden Verfahrens
CN105358071B (zh)	2013-06-21	2018-07-31	弗罗桑医疗设备公司	真空膨胀的干组合物和用于保留该干组合物的注射器
WO2015086028A1 (fr)	2013-12-11	2015-06-18	Ferrosan Medical Devices A/S	Composition sèche comprenant un améliorateur d'extrusion
US20150216947A1 (en) *	2014-02-03	2015-08-06	George D. Petito	Method and composition for tissue/cell repair
US11046818B2 (en)	2014-10-13	2021-06-29	Ferrosan Medical Devices A/S	Dry composition for use in haemostasis and wound healing
CN107206165B (zh)	2014-12-24	2020-10-23	弗罗桑医疗设备公司	用于保持并混合第一和第二物质的注射器
CA2986981A1 (fr)	2015-07-03	2017-01-12	Ferrosan Medical Devices A/S	Seringue pour melanger deux composants et pour conserver un vide dans une condition de stockage
EP3790600B1 (fr)	2018-05-09	2023-12-27	Ferrosan Medical Devices A/S	Procédé de préparation d'une composition hémostatique
DE102018218429A1 (de)	2018-10-29	2020-04-30	Heraeus Medical Gmbh	Vorrichtung zur temporären, lokalen Applikation von Fluiden
EP3795196B1 (fr)	2019-09-18	2022-05-11	Heraeus Medical GmbH	Dispositif d'application temporaire et locale de fluides
CA3091601A1 (fr)	2019-09-18	2021-03-18	Heraeus Medical Gmbh	Dispositif d`application locale temporaire de fluides
EP3854437B1 (fr)	2020-01-27	2022-01-19	Heraeus Medical GmbH	Dispositif d'application temporaire et locale des fluides
EP3831426B1 (fr)	2019-12-05	2025-07-09	Heraeus Medical GmbH	Dispositif d'application locale de fluides pharmaceutiques
WO2021226373A2 (fr)	2020-05-08	2021-11-11	Gallant Pet, Inc.	Compositions de cellules régénératives d'origine utérine et leurs utilisations
US20220211921A1 (en) *	2021-01-06	2022-07-07	Medtronic Inc.	Surgical system and methods of use
EP4094797B1 (fr)	2021-05-28	2023-04-05	Heraeus Medical GmbH	Dispositif d'application d'un fluide pharmaceutique
EP4395796A4 (fr)	2021-09-01	2024-12-25	Shanghai Qisheng Biological Preparation Co., Ltd.	Régénération de cartilage à l'aide de compositions de collagène injectables polymérisables in situ contenant des chondrocytes ou des cellules souches
WO2023125689A1 (fr)	2021-12-28	2023-07-06	Shanghai Qisheng Biological Preparation Co., Ltd.	Compositions de copolymère d'acide hyaluronique-collagène et leurs applications médicales
WO2023191003A1 (fr) *	2022-03-31	2023-10-05	センジュユーエスエー、インコーポレイテッド	Matériau médical
EP4649987A1 (fr)	2024-05-17	2025-11-19	Heraeus Medical GmbH	Système d'administration médicale avec vannes fendues à fermeture automatique

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3126884A (en) *		1964-03-31		Method of preserving animal tissue
CH139949A (de)	1928-05-23	1930-05-15	Patent Treuhand Ges Fuer Elektrische Gluehlampen Mbh	Elektrische Lampe.
CH141238A (de)	1929-10-08	1930-07-31	Sahli Kummer Emil	Schlepprechen.
CH144375A (de)	1930-01-10	1930-12-31	Oederlin Cie Ag	Kupplungskopf für Gummischlauch mit Metallschlauchhülle.
US2967802A (en) *	1957-12-02	1961-01-10	Diamond Lab	Hydrated calcium phosphate gelantigen composition and method of preparing same
US3400199A (en) *	1965-02-26	1968-09-03	Leslie L. Balassa	Wound-healing cartilage powder
DE1183629B (de) *	1962-12-21	1964-12-17	Behringwerke Ag	Verfahren zur Stabilisierung biologisch aktiven Materials
US3478146A (en) *	1965-02-26	1969-11-11	Leslie L Balassa	Wound-healing cartilage powder extracting process
FR1441817A (fr)	1965-05-17	1966-06-10	Spofa Vereinigte Pharma Werke	Procédé pour la préparation de mousse collagène ainsi que les mousses collagènes conformes à celles obtenues par le présent procédé ou procédé similaire
US3435117A (en) *	1966-03-09	1969-03-25	Ethicon Inc	Collagen fibril matrix pharmaceuticals
US3435110A (en) *	1966-03-21	1969-03-25	Ethicon Inc	Collagen fibril matrix pharmaceuticals
US3469003A (en) *	1966-04-01	1969-09-23	Haver Lockhart Lab Inc	Injectable reconstituted collagen fluid adjuvant for vaccines and other drugs
GB1195061A (en) *	1966-05-27	1970-06-17	Fmc Corp	Coated Structures and Methods of Forming Them.
US3458397A (en) *	1966-12-08	1969-07-29	Squibb & Sons Inc	Process for producing osteogenic material
DE1766340A1 (de) *	1967-05-19	1971-07-01	Vyzk Ustav Pletarzsky	Textil-Kollagenprothese
US3443261A (en) *	1967-09-01	1969-05-13	Fmc Corp	Prosthetic structures from microcrystalline collagen
FR1604134A (fr) *	1967-09-26	1971-07-12
US3551560A (en) *	1967-10-02	1970-12-29	Heinrich F Thiele	Process of reconstructing tendons,cartilage,nerve sheaths,and products
US3563925A (en) *	1967-12-20	1971-02-16	Ceskoslovenska Akademie Ved	Composition containing interlocked foams of partly tanned collagen and cross-linked glycol methacrylate polymer
US3639577A (en) *	1968-02-23	1972-02-01	Haver Lockhart Lab Inc	Injectable adjuvant,method of preparing same and compositions including such adjuvant
DE1811290C3 (de)	1968-11-27	1980-02-14	Milos Dr.Med Dr.Se. 8000 Muenchen Chvapil	Verfahren zur Herstellung von Kollagenfasergeflechten in Form von filzartigen Membranen oder schwammartigen Schichten
US3823212A (en) *	1968-11-27	1974-07-09	Freudenberg C Fa	Process for the production of collagen fiber fabrics in the form of felt-like membranes or sponge-like layers
US3790507A (en) *	1969-03-10	1974-02-05	Research Corp	Plastic bone composition
US3887699A (en) *	1969-03-24	1975-06-03	Seymour Yolles	Biodegradable polymeric article for dispensing drugs
US3773919A (en) *	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US3691281A (en) *	1970-02-02	1972-09-12	Fmc Corp	Microcrystalline collagen,method of making same and foods,pharmaceuticals and cosmetics containing same
US3821371A (en) *	1970-02-02	1974-06-28	Avicon Inc	Pharmaceutical compositions containing microcrystalline collagen,a water-insoluble,ionizable,partial salt of collagen
CA962806A (en) *	1970-06-04	1975-02-18	Ontario Research Foundation	Surgical prosthetic device
US3846542A (en) *	1970-07-20	1974-11-05	Kulzer & Co Gmbh	Acrylic tooth-filling composition containing boric acid-releasing compound
US3703575A (en) *	1970-12-23	1972-11-21	Heinrich Thiele	Reconstructed cartilaginous tissue and method of implanting it into the human or animal body
US3772432A (en) *	1971-01-11	1973-11-13	Lescarden Ltd	Cartilage compositions for dental use
US3787900A (en) *	1971-06-09	1974-01-29	Univ Iowa State Res Found	Artificial bone or tooth prosthesis material
JPS5221200B2 (fr) *	1971-09-22	1977-06-08
US3758660A (en) *	1971-10-15	1973-09-11	Avicon Inc	Method of forming structures from microcrystalline collagen
US3867190A (en) *	1971-10-18	1975-02-18	American Cyanamid Co	Reducing capillarity of polyglycolic acid sutures
US3767437A (en) *	1971-10-20	1973-10-23	Avicon Inc	Phosthetic structures derived from collagen
US3808606A (en) *	1972-02-22	1974-05-07	R Tronzo	Bone implant with porous exterior surface
US4016252A (en) *	1972-04-06	1977-04-05	Institut Pasteur	Calcium phosphate gel for adsorbing vaccines
FR2181426B1 (fr) *	1972-04-06	1974-12-20	Pasteur Institut
US3991766A (en) *	1973-05-31	1976-11-16	American Cyanamid Company	Controlled release of medicaments using polymers from glycolic acid
US3976071A (en) *	1974-01-07	1976-08-24	Dynatech Corporation	Methods of improving control of release rates and products useful in same
US4141864A (en) *	1974-03-15	1979-02-27	University Of Virginia Alumni Patents Foundation	Osseous cement composition
IL44697A (en) *	1974-04-23	1977-06-30	Sneer M	Dental implants
US3918100A (en) *	1974-05-13	1975-11-11	Us Navy	Sputtering of bone on prostheses
FR2278348A2 (fr) *	1974-06-28	1976-02-13	Rhone Poulenc Ind	Articles chirurgicaux bioresorbables
US3949073A (en) *	1974-11-18	1976-04-06	The Board Of Trustees Of Leland Stanford Junior University	Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution
US4027676A (en) *	1975-01-07	1977-06-07	Ethicon, Inc.	Coated sutures
DE2517452C3 (de) *	1975-04-19	1978-11-02	Fa. Carl Freudenberg, 6940 Weinheim	Kollagenfolie für kosmetische Anwendung
JPS5842473B2 (ja) *	1975-09-02	1983-09-20	シャープ株式会社	ハクマクｅｌソシノクドウホウホウ
DE2620907C3 (de)	1976-05-12	1984-09-20	Battelle-Institut E.V., 6000 Frankfurt	Verankerung für hochbelastete Endoprothesen
NL7704659A (nl) *	1976-05-12	1977-11-15	Battelle Institut E V	Beendervervangings-, beenderverbindings- of prothesenverankeringsmateriaal.
DE2620890C3 (de)	1976-05-12	1987-09-10	Battelle-Institut eV, 6000 Frankfurt	Plastische Masse auf der Basis von gesinterten Calciumphosphaten für implantierbare Knochenersatz-, Knochenverbund- oder Prothesenverankerungswerkstoffe
DE2620891C3 (de)	1976-05-12	1989-06-29	Battelle-Institut eV, 6000 Frankfurt	Fester, resorbierbarer Knochenersatz-, Knochenverbund- oder Prothesenverankerungswerkstoff
DE2659916A1 (de) *	1976-05-14	1977-11-24	Pfaudler Werke Ag	Verfahren zur herstellung eines implantats mit schleifender oberflaeche
DE2650306A1 (de) *	1976-11-02	1978-05-03	Merck Patent Gmbh	Antibakteriell wirkender wundverband und verfahren zu seiner herstellung
AR216922A1 (es) *	1976-11-11	1980-02-15	Merck Patent Gmbh	Procedimiento para la fabricacion de un medio quirurgico
DE2724814C3 (de) *	1977-06-02	1980-03-27	Kulzer & Co Gmbh, 6380 Bad Homburg	Vorprodukt fur die Zubereitung von Knochenzement
JPS5416671A (en) *	1977-07-08	1979-02-07	Tokyo Shibaura Electric Co	Inspection apparatus for print wire board
US4156943A (en) *	1977-08-24	1979-06-05	Collier John P	High-strength porous prosthetic device and process for making the same
US4164559A (en) *	1977-09-21	1979-08-14	Cornell Research Foundation, Inc.	Collagen drug delivery device
US4195366A (en) *	1977-12-23	1980-04-01	Sterling Drug Inc.	Whitlockite ceramic
DE2843963A1 (de) *	1978-10-09	1980-04-24	Merck Patent Gmbh	Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin

1978
- 1978-10-09 DE DE19782843963 patent/DE2843963A1/de active Granted
1979
- 1979-10-01 CS CS796641A patent/CS221526B2/cs unknown
- 1979-10-04 IL IL58397A patent/IL58397A/xx unknown
- 1979-10-05 DD DD79216048A patent/DD146548A5/de unknown
- 1979-10-05 GB GB7934734A patent/GB2032777B/en not_active Expired
- 1979-10-05 CA CA000337155A patent/CA1142433A/fr not_active Expired
- 1979-10-05 FR FR7924846A patent/FR2438479A1/fr active Granted
- 1979-10-08 NL NL7907450A patent/NL7907450A/nl not_active Application Discontinuation
- 1979-10-08 BE BE0/197515A patent/BE879252A/fr not_active IP Right Cessation
- 1979-10-08 SE SE7908313A patent/SE434013B/sv not_active IP Right Cessation
- 1979-10-08 AT AT0655079A patent/AT371724B/de not_active IP Right Cessation
- 1979-10-08 ZA ZA00795356A patent/ZA795356B/xx unknown
- 1979-10-08 IT IT50493/79A patent/IT1164832B/it active
- 1979-10-08 AU AU51556/79A patent/AU535839B2/en not_active Ceased
- 1979-10-08 ES ES484821A patent/ES484821A0/es active Granted
- 1979-10-09 HU HU79ME2306A patent/HU180019B/hu unknown
- 1979-10-09 CH CH907679A patent/CH642845A5/de not_active IP Right Cessation
- 1979-10-09 US US06/082,520 patent/US4291013A/en not_active Expired - Lifetime
- 1979-10-09 JP JP12955379A patent/JPS5553214A/ja active Pending
1981
- 1981-06-15 US US06/273,291 patent/US4347234A/en not_active Expired - Fee Related

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3411957A1 (de) *	1983-03-31	1984-10-04	Genetic Laboratories, Inc., St. Paul, Minn.	Verfahren zur herrichtung von tierischem oder menschlichem gewebe zur verwendung als verbandsmaterial
DE3317390A1 (de) *	1983-05-13	1984-11-15	Hoechst Ag, 6230 Frankfurt	Pharmazeutisches mittel zur behandlung von knocheninfektionen
DE3523023A1 (de) *	1985-06-27	1987-01-08	Ruhland Nachf Gmbh Dr	Silberhaltige kollagenschwaemme oder kollagenfascien und deren verwendung zur herstellung eines abdeckmaterials fuer hautlaesionen
DE3832162A1 (de) *	1988-09-22	1990-04-12	Lohmann Therapie Syst Lts	Verfahren zur herstellung von kollagenschaeumen in form endloser baender und verwendung in medizin, kosmetik und hygiene
DE3912693A1 (de) *	1989-04-18	1990-10-25	Bioprotan Handels Gmbh	Verbundmaterial fuer kosmetische zwecke
DE4143239A1 (de) *	1991-12-31	1993-07-01	Joerg Dipl Chem Schierholz	Pharmazeutische wirkstoffe enthaltende implantierbare vorrichtung aus einem polymeren material sowie verfahren zu deren herstellung
DE102019000322A1 (de)	2019-01-14	2020-07-16	Beuth Hochschule Für Technik Berlin	Polymerzusammensetzung mit antiseptischen Eigenschaften und Verfahren zur Herstellung
DE102019000321A1 (de)	2019-01-14	2020-07-16	Beuth Hochschule Für Technik Berlin	Orale Polymerzusammensetzung mit verzögerter Freisetzung
DE102020007979A1 (de)	2020-12-29	2022-06-30	Charité Universitätsmedizin Institut für Mikrobiologie und Infektionsimmunologie	Zusammensetzung zur Behandlung von lnfektionen mit Coronaviren

Also Published As

Publication number	Publication date
AU535839B2 (en)	1984-04-05
GB2032777A (en)	1980-05-14
AT371724B (de)	1983-07-25
DE2843963A1 (de)	1980-04-24
ATA655079A (de)	1982-12-15
IT7950493A0 (it)	1979-10-08
US4291013A (en)	1981-09-22
HU180019B (en)	1983-01-28
GB2032777B (en)	1983-05-11
IT1164832B (it)	1987-04-15
ES8101886A1 (es)	1980-12-16
IL58397A (en)	1982-07-30
JPS5553214A (en)	1980-04-18
IL58397A0 (en)	1980-01-31
SE434013B (sv)	1984-07-02
CS221526B2 (en)	1983-04-29
SE7908313L (sv)	1980-04-10
ES484821A0 (es)	1980-12-16
DE2843963C2 (fr)	1988-02-18
NL7907450A (nl)	1980-04-11
BE879252A (fr)	1980-04-08
US4347234A (en)	1982-08-31
FR2438479A1 (fr)	1980-05-09
ZA795356B (en)	1980-09-24
AU5155679A (en)	1980-04-17
FR2438479B1 (fr)	1983-12-30
CH642845A5 (de)	1984-05-15
CA1142433A (fr)	1983-03-08

Publication	Publication Date	Title
DE2843963C2 (fr)	1988-02-18
EP0202445B1 (fr)	1991-02-20	Formes pharmaceutiques du type dépôt contenant des agents cytostatiques
EP0058867B1 (fr)	1986-09-10	Procédé pour fabriquer une céramique d'os de tricalciumphosphate à utiliser comme implantation d'os, en particulier pour remplir des espaces vides ou pour fixer des éclats d'os après une fracture et les corps moulés de céramique de tricalciumphosphate fabriqués d'après ce procédé
DE60005049T2 (de)	2004-07-08	Bioabsorbierbare arzneimittelabgabevorrichtung
DE69224131T2 (de)	1998-04-30	Polymerzusammensetzungen zur Verwendung als Implantate mit verzögerter Abgabe
DE69332210T2 (de)	2003-04-24	Biologisch abbaubares, schmelzgesponnenes abgabesystem zur kontrollierten freisetzung
EP0519293B1 (fr)	1998-12-09	Matériau d'implant
EP2037972B1 (fr)	2011-09-21	Utilisation de gélatine et de transglutaminase pour produire un adhésif médical à réticulation
EP1243258B1 (fr)	2004-02-18	Production et utilisation d'une préparation comprenant un ou plusieurs antibiotiques
WO1998007456A1 (fr)	1998-02-26	Procede pour la fabrication de ciments osseux contenant des principes actifs
EP0582186A1 (fr)	1994-02-09	Procédé de préparation de formes pharmaceutiques solides à libération prolongée en deux étapes
EP1243255B1 (fr)	2005-12-07	Procédé de préparation de compositions antibiotiques
DE2917037B1 (de)	1980-04-17	Parenterale arzneimittelhaltige partiell resorbierbare Mehrkomponentenmasse auf Basis von polymeren Stoffen
EP0061108B1 (fr)	1986-12-30	Article à être implanté dans l'os, procédé pour sa fabrication et son utilisation
EP0807432A2 (fr)	1997-11-19	Procédé pour la fabrication d'une préparation médicale contenant du sulfate de calcium et une préparation médicale contenant du sulfate de calcium
DE3841397C2 (fr)	1992-11-12
EP1220656B1 (fr)	2003-08-13	Corps moules contenant une phase externe amphiphile et une phase interne lipophile
DD224491A5 (de)	1985-07-10	Verfahren zur herstellung eines resorbierbaren antibiotika-depots
JPH04279520A (ja)	1992-10-05	骨内部埋め込み用製剤
JP2009502928A (ja)	2009-01-29	術後疼痛軽減用組成物および軽減方法
DE3110681A1 (de)	1982-09-30	Material fuer knochenimplantate, verfahren zu seiner herstellung und seine verwendung
EP0676408B1 (fr)	2001-11-14	Procédé de préparation d'agents antibactériens et leur utilisation
JP2817966B2 (ja)	1998-10-30	生体への刺激を軽減した硬組織補填用練和物及びその製造方法
DE102023200788A1 (de)	2024-08-01	Festes Lyophilisat und Verfahren zur Herstellung
DD205069A1 (de)	1983-12-21	Verfahren zur herstellung eines therapeutischen mittels

DD146548A5 - Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (1)

Publications (1)

Family

ID=6051759

Family Applications (1)

Country Status (19)

Cited By (9)

Families Citing this family (250)

Family Cites Families (62)

Cited By (9)

Also Published As

Similar Documents